Clinical trials: Stage IIB Prostate Cancer AJCC v7
Prostate Cancer
Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin, leuprolide, flutamide, or bicalutamide may stop the adrenal glands from producing androgens.
- Trial name
- NCT00032006
- Testing
- brachytherapy, radiation therapy
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
This pilot phase II trial studies how well giving bevacizumab works in treating patients with relapsed prostate cancer that did not respond to hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01656304
- Testing
- bevacizumab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Stage II Prostate Adenocarcinoma, Stage IIB Prostate Cancer
Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery
This phase I trial studies the side effects and the best dose of hypofractionated stereotactic body radiation therapy (SBRT) in treating patients with prostate cancer that was removed by surgery.
- Conditions
- Stage II Prostate Adenocarcinoma, Stage IIB Prostate Cancer, Stage III Prostate Adenocarcinoma
- Trial name
- NCT02446366
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Southern California
Prostate Cancer
MRI in Diagnosing Prostate Cancer
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help find prostate cancer and learn the extent of disease.
- Trial name
- NCT01292291
- Testing
- biologic sample preservation procedure, laboratory biomarker analysis, study of socioeconomic and demographic variables
- Volunteers
- 714 people
- Sponsor
- University College London Hospitals
Prostate Cancer
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone.
- Trial name
- NCT00021450
- Testing
- bicalutamide, goserelin acetate, adjuvant therapy
- Where
- 20 sites in Belgium, Cyprus and 9 more
- Volunteers
- 819 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Nonmalignant Neoplasm, Prostate Cancer
MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer
RATIONALE: Diagnostic procedures, such as MRI and magnetic resonance spectroscopy imaging, may help in learning how well dutasteride works in patients with benign prostatic hypertrophy and low-risk prostate cancer.
- Trial name
- NCT00706966
- Testing
- dutasteride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Implant Radiation Therapy Using Radioactive Iodine in Treating Patients With Localized Prostate Cancer
RATIONALE: Implant radiation therapy delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- J-POPS (NCT00534196)
- Testing
- Permanent iodine-125 (Brachytherapy)
- Where
- 31 sites in Japan
- Volunteers
- 6,927 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Pain, Prostate Cancer
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00005960
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 6 sites in United States
- Sponsor
- Amgen
Prostate Cancer
Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00955435
- Testing
- Non-interventional, Protein expression analysis, Proteomic profiling
- Where
- 2 sites in Ireland
- Volunteers
- 60 people
- Sponsor
- Cancer Trials Ireland
Prostate Cancer
Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer
RATIONALE: Nordihydroguaiaretic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nordihydroguaiaretic acid…
- Trial name
- NCT00313534
- Testing
- masoprocol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer
RATIONALE: Celecoxib may be an effective treatment for early stage prostate cancer. It is not yet known if celecoxib is more effective than no treatment before surgery for prostate cancer.
- Trial name
- NCT00022399
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Brachytherapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy through seeds implanted into the prostate may kill more tumor cells.
- Trial name
- NCT00003312
- Testing
- iodine I 125
- Where
- 258 sites in United States, Canada
- Volunteers
- 95 people
- Sponsor
- Radiation Therapy Oncology Group
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
High-Dose Stereotactic Radiation for Prostate Cancer
This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01664130
- Testing
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00376792
- Testing
- docetaxel, active surveillance, adjuvant therapy
- Where
- 8 sites in Denmark, Finland and 3 more
- Volunteers
- 396 people
- Sponsor
- Scandinavian Prostate Cancer Group
Prostate Cancer
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy given with QS21 in treating patients who have progressive prostate cancer.
- Trial name
- NCT00003819
- Testing
- QS21, TF(c)-KLH conjugate vaccine, Thomsen-Friedenreich antigen
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Prostate Cancer, Stage I Prostate Cancer
Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy
This randomized pilot clinical trial studies atorvastatin calcium in preventing metabolic syndrome in patients with prostate cancer receiving long-term androgen-deprivation therapy.
- Conditions
- Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT01555632
- Testing
- atorvastatin calcium
- Sponsor
- University of Nebraska
Prostate Cancer
Positron Emission Tomography in Prostate Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography using carbon-11 acetate, may help find metastases from prostate cancer and may help predict whether prostate cancer will come back after treatment.
- Trial name
- NCT00121212
- Testing
- carbon-11 acetate PET scan
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer
Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00967954
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, DNA analysis
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Cancer Research UK
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma
RElugolix VErsus LeUprolide Cardiac Trial
This clinical trial investigates the impact of prostate cancer treatment, specifically androgen deprivation therapy (ADT), on the heart and coronary vessels among men with localized, non-metastatic prostate cancer undergoing…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- REVELUTION (NCT05320406)
- Testing
- Radiation therapy, Leuprolide, Relugolix
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Emory University
Prostate Cancer
Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer
RATIONALE: Calcitriol may help prostate cancer cells develop into normal cells. Zoledronate may delay or prevent the formation of bone metastases.
- Trial name
- NCT00004928
- Testing
- calcitriol, zoledronic acid
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center